IL-33/ST2信号通路与卒中

doi:10.3969/j.issn.1673-5765.2019.04.018

摘要/Abstract

摘要：

IL-33/ST2信号通路与卒中关系密切。该信号通路不仅可以影响动脉粥样硬化，还可以影响卒中的发病、严重程度、卒中后炎症反应及预后转归。本文就IL-33/ST2信号通路在卒中中的研究进展进行阐述，旨在为今后研究和临床实践提供思路。

文章导读： IL-33/ST2信号通路与卒中密切相关，可通过影响动脉粥样硬化、卒中后炎症反应影响卒中的发生发展、严重程度及预后。

关键词: 白细胞介素-33; 炎症; 生物标志物; 卒中

Abstract:

The IL-33/ST2 signal pathway is closely related to stroke. This signal pathway not only involves in the atherogenesis, but also in stroke occurrence and development, inflammation reaction after stroke and prognosis of stroke. This article reviewed the advance in role of IL-33/ST2 signal pathway in stroke, to provide ideas for future research and clinical practice.

Key words: Interleukin-33; Inflammation; Biomarker; Stroke

田璇，裴璐璐，王潇，刘新静，许予明，宋波. IL-33/ST2信号通路与卒中[J]. 中国卒中杂志, 2019, 14(04): 385-388.

TIAN Xuan, PEI Lu-Lu, WANG Xiao, LIU Xin-Jing, XU Yu-Ming,SONG Bo. Advance in IL-33/ST2 Signal Pathway in Stroke[J]. Chinese Journal of Stroke, 2019, 14(04): 385-388.

参考文献

[1] LIU M，WU B，WANG W Z，et al. Stroke in

China：epidemiology，prevention，and management

strategies[J]. Lancet Neurol，2007，6（5）：456-464.

[2] BRAUN H，AFONINA I S，MUELLER C，et

al. Dichotomous function of IL-33 in health and

disease：from biology to clinical implications[J/OL].

Biochem Pharmacol，2018，148：238-252. https：//

doi.org/10.1016/j.bcp.2018.01.010.

[3] CARRIERE V，ROUSSEL L，ORTEGA N，et al.

IL-33，the IL-1-like cytokine ligand for ST2 receptor，

is a chromatin-associated nuclear factor in vivo[J].

Proc Natl Acad Sci USA，2007，104（1）：282-287.

[4] MOUSSION C，ORTEGA N and GIRARD J P. The

IL-1-like cytokine IL-33 is constitutively expressed

in the nucleus of endothelial cells and epithelial

cells in vivo：a novel 'alarmin'?[J/OL]. PLoS One，

2008，3（10）：e3331. https：//doi.org/10.1371/journal.

pone.0003331.

[5] YANG Y，LIU H，ZHANG H，et al. ST2/IL-33-

Dependent microglial response limits acute ischemic

brain injury[J]. J Neurosci，2017，37（18）：4692-

4704.

[6] GRIESENAUER B，PACZESNY S. The ST2/IL-33 axis in immune cells during inflammatory diseases[J/

OL]. Front Immunol，2017，8：475. https：//doi.

org/10.3389/fimmu.2017.00475.

[7] LIEW F Y，GIRARD J P，TURNQUIST H R.

Interleukin-33 in health and disease[J]. Nat Rev

Immunol，2016，16（11）：676-689.

[8] PASCUAL-FIGAL D A，JANUZZI J L. The biology

of ST2：the International ST2 Consensus Panel[J].

Am J Cardiol，2015，115（7 Suppl）：3B-7B.

[9] MARZULLO A，AMBROSI F，INCHINGOLO

M，et al. ST2L transmembrane receptor expression：

an immunochemical study on endarterectomy

samples[J/OL]. PLoS One，2016，11（5）：e0156315.

https：//www.doi.org/10.1371/journal.pone.0156315.

[10] YAMAMOTO M，UMEBASHI K，TOKITO A，et al.

Interleukin-33 induces growth-regulated oncogene-α

expression and secretion in human umbilical vein

endothelial cells[J]. Am J Physiol Regul Integr Comp

Physiol，2017，313（3）：R272-R279.

[11] ALTARA R，GHALI R，MALLAT Z，et al.

Conflicting vascular and metabolic impact of the

IL-33/sST2 axis[J]. Cardiovasc Res，2018，114（12）：

1578-1594.

[12] ATES I，OZKAYAR N，ATES H，et al. Elevated

circulating sST2 associated with subclinical

atherosclerosis in newly diagnosed primary

hypertension[J]. Hypertens Res，2016，39（7）：513-

518.

[13] GUO L，ZHOU X，GUO X，et al. Association of

interleukin-33 gene single nucleotide polymorphisms

with ischemic stroke in north Chinese population[J/

OL]. BMC Med Genet，2013，14：109. https：//doi.

org/10.1186/1471-2350-14-109.

[14] KORHONEN P，KANNINEN K M，LEHTONEN

Š，et al. Immunomodulation by interleukin-33

is protective in stroke through modulation of

inflammation[J/OL]. Brain Behav Immun，2015，49：

322-336. https：//doi.org/10.1016/j.bbi.2015.06.013.

[15] LUO Y，ZHOU Y，XIAO W，et al. Interleukin-33

ameliorates ischemic brain injury in experimental

stroke through promoting Th2 response and

suppressing Th17 response[J/OL]. Brain Res，

2015，1597：86-94. https：//doi.org/10.1016/

j.brainres.2014.12.005.

[16] LI Q，LIN Y S，HUANG W S，et al. Serum IL-33 is

a novel diagnostic and prognostic biomarker in acute

ischemic stroke[J]. Aging Dis，2016，7（5）：614-622.

[17] LIU J，XING Y，GAO Y，et al. Changes in serum

interleukin-33 levels in patients with acute cerebral

infarction[J]. J Clin Neurosci，2014，21（2）：298-

300.

[18] DIEPLINGER B，BOCKSRUCKER C，EGGER

M，et al. Prognostic Value of inflammatory and

cardiovascular biomarkers for prediction of 90-

day all-cause mortality after acute ischemic strokeresults

from the linz stroke unit study[J]. Clin Chem，

2017，63（6）：1101-1109.

[19] ANDERSSON C，PREIS S R，BEISER A，et al.

Associations of circulating growth differentiation

Factor-15 and ST2 concentrations with subclinical

vascular brain injury and incident stroke[J]. Stroke，

2015，46（9）：2568-2575.

[20] WOLCOTT Z，BATRA A，BEVERS M B，et al.

Soluble ST2 predicts outcome and hemorrhagic

transformation after acute stroke[J]. Ann Clin Transl

Neurol，2017，4（8）：553-563.

[21] CHEN W，LIN A，YU Y，et al. Serum soluble ST2

as a novel inflammatory marker in acute ischemic

stroke[J]. Clin Lab，2018，64（9）：1349-1356.

[22] GAO Y，MA L，LUO C L，et al. IL-33 exerts

neuroprotective effect in mice intracerebral

hemorrhage model through suppressing

inflammation/apoptotic/autophagic pathway[J]. Mol

Neurobiol，2017，54（5）：3879-3892.

[23] KANDA M，OHTO-OZAKI H，KUROIWA K，et al.

Elevation of ST2 protein levels in cerebrospinal fluid

following subarachnoid hemorrhage[J]. Acta Neurol

Scand，2006，113（5）：327-333.

[24] HUANG L T，LI H，SUN Q，et al. IL-33 expression

in the cerebral cortex following experimental

subarachnoid hemorrhage in rats[J]. Cell Mol

Neurobiol，2015，35（4）：493-501.

[25] GONG J，ZHU Y，YU J，et al. Increased serum

interleukin-33 concentrations predict worse

prognosis of aneurysmal subarachnoid hemorrhage[J/

OL]. Clin Chim Acta，2018，486：214-218. https：//

doi.org/10.1016/j.cca.2018.08.011.